THBP-6

THBP-6 is a novel small molecule benzopyran derivative, specifically identified as a 2-(toluene sulfonamido)-3-cyano-7,7-dimethyl-4-substituted phenyl-5,6,7,8-tetrahydrobenzopyran-5-one. Developed by researchers at Manglayatan University and St Mary's College of Pharmacy, it was synthesized through a Knoevenagel condensation followed by a Michael addition mechanism. In preclinical studies, THBP-6 demonstrated potent anticancer activity against MCF-7 breast cancer cells, exhibiting the highest cytotoxic activity among a series of synthesized derivatives with an IC50 value of 20.99 µg/mL. Its efficacy is attributed to optimal electronic and steric factors, as well as enhanced lipophilicity provided by its sulfonamide and cyano substitutions, which are believed to promote strong binding to cellular targets.